Promising Results of Zidesamtinib in Treating ROS1-Positive NSCLC Patients Post-TKI Therapy
Zidesamtinib shows promising durable responses in ROS1-positive NSCLC patients, including those with brain metastases and prior TKI treatment, demonstrating potential as a targeted therapy option.
Zidesamtinib, an innovative next-generation ROS1 tyrosine kinase inhibitor (TKI), has demonstrated significant clinical activity and sustained responses in patients with ROS1-positive non-small cell lung cancer (NSCLC) who previously undergone TKI treatment. This highly selective, brain-penetrant, and TRK-sparing agent was evaluated in the Phase I/II ARROS-1 trial, with results presented at the 2025 World Conference on Lung Cancer by Dr. Alexander Edward Drilon from Memorial Sloan Kettering Cancer Center.
The trial enrolled patients with advanced or metastatic ROS1+ NSCLC, with a focus on those who had received prior TKI therapies. The pivotal analysis included 117 efficacy-evaluable patients who started on a daily dose of 100 mg zidesamtinib before May 31, 2024. Additionally, preliminary data from 35 TKI-naive patients showed remarkable outcomes.
Among the TKI pre-treated group, which had a median of two prior therapies—including multiple ROS1 TKIs like lorlatinib, repotrectinib, and taletrectinib—durable responses were observed, even in patients with brain metastases or ROS1 mutations like G2032R. The objective response rate was 44%, and at 12 months, 78% of responders maintained response. Notably, patients with prior crizotinib or entrectinib alone exhibited an ORR of 51%, with a 12-month DOR rate of 93%.
In the TKI-naive cohort, the results were particularly encouraging with an ORR of 89% and a 96% DOR rate at 12 months. Intracranial activity was notable, with an intracranial ORR of 83%, including complete responses, and no CNS progression observed at data cutoff.
The treatment was generally well tolerated; common adverse events included peripheral edema, constipation, elevated CPK, fatigue, and dyspnea, with most being manageable and severe cases being rare. Dose reductions were needed in 10% of patients, and only 2% discontinued treatment due to side effects.
Dr. Drilon emphasized that zidesamtinib’s design allows for significant disease control in patients with few options left, especially given its brain-penetrance and selectivity. The positive findings in both pre-treated and treatment-naive populations advocate for further development of this promising agent.
Source: https://medicalxpress.com/news/2025-09-zidesamtinib-durable-responses-ros1-tki.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Discovery of a Tiny Brain Region Crucially Involved in Motor Learning During Reaching Movements
A recent study from the University of Osaka reveals that a small brain region called the parvocellular red nucleus plays a key role in motor learning by signaling errors during reaching movements, opening new avenues for neurorehabilitation.
Impact of APOE Protein Variants on Microglia Function in Alzheimer's Disease
A groundbreaking study uncovers how different APOE protein variants influence microglial functions, affecting Alzheimer's disease progression and offering new targets for personalized therapies.
Innovative Approach to Slowing Glioblastoma Growth by Blocking Brain Damage
New research suggests that blocking brain damage caused by glioblastoma may slow tumor growth and preserve neurological function, opening new pathways for early intervention strategies.
Employment Can Boost Recovery in Individuals with Alcohol Use Disorder
Work and employment support significantly improve recovery outcomes for individuals treating alcohol use disorder, reducing drinking frequency and enhancing quality of life.